HELSINKI, Finland, Aug. 12, 2014 – Nexstim (the "Company"), the world leader in Navigated Brain Stimulation, announces the appointment of Mikko Karvinen as its new Chief Financial Officer effective as of 18 August.
Mr Karvinen (aged 37) started his career as a financial analyst at OP Bank Group, Vaisala Oyj (in Boston and Boulder, USA) and Automaster Oy. In 2009 he was appointed CFO at SSH Communications Security Oyj, a market leader in encrypted network security solutions before moving to Innofactor PLC, a leading Nordic IT solution provider, as CFO, in 2012. SSH and Innofactor are listed on the Nasdaq OMX Helsinki Stock Exchange.
Janne Huhtala, Chief Executive Officer of Nexstim, commented:"Mikko is an outstanding addition to the management team. His experience as CFO of some of Finland ´s best technology systems companies will be a significant asset and we welcome him to the Company."
Mikko Karvinen added:"I am exteremely excited to join Nexstim and I look forward to being a part of building this therapy technology to help stroke patients."
Janne Huhtala, Chief Executive Officer
+358 (0)40 8615046
Consilium Strategic Communications
Mary-Jane Elliott / Amber Bielecka / Ivar Milligan / Laura Thornton
+44 (0)20 3709 5700
Founded in Finland in 2000, Nexstim is the world leader in Navigated Brain Stimulation (NBS) with image-guided Transcranial Magnetic Stimulation (TMS). The company is committed to improving the quality of life of patients. Nexstim has pioneered the technology for brain diagnostics with the Navigated Brain Stimulation (NBS) System as the first and only FDA-cleared and CE-marked navigated TMS (nTMS) device for pre-surgical mapping of the motor and speech cortices. The advanced technology providing navigation to TMS has led NBS to be recognized as the emerging standard for pre-operative direct functional mapping. Nexstim initiated its two year multicenter clinical trial on the therapeutic effects of nTMS for stroke rehabilitation in June 2014 with Navigated Brain Therapy (NBT).
Caution: Nexstim ´s NBS System is cleared by the FDA for assessment of the motor and speech cortices for pre-procedural planning. The NBT System is not cleared for commercial distribution in the United States.